Chemours CO

The Chemours Company has entered into a consent decree with the EPA and WVDEP to resolve PFAS-related environmental claims across three major manufacturing facilities.

The Chemours Company reported Q1 2026 net sales of $1.4 billion, bolstered by record Thermal & Specialized Solutions performance despite operational headwinds in other segments.

The Chemours Company completed a private offering of $700 million in 7.875% senior unsecured notes due 2034 to refinance existing debt.

The Chemours Company successfully upsized and priced a private offering of $700 million in 7.875% senior unsecured notes due 2034 to refinance existing debt.

Chemours reports mixed Q4 and full year 2025 results, with strong Opteon Refrigerants growth in TSS offsetting headwinds in other segments, while providing a positive 2026 outlook.

The Chemours Company announced the sale of its former titanium dioxide manufacturing site in Kuan Yin, Taiwan, for approximately $360 million, with proceeds earmarked for debt reduction.

Chemours reported a net loss of $29 million for Q1 2026, impacted by operational disruptions and ongoing legal costs.

Chemours reported a net loss of $325 million for the first nine months of 2025, driven by significant PFAS litigation settlements and operational challenges in its Titanium Technologies and Advanced Performance Materials segments.

The Chemours Company reported a significant net loss for the second quarter and first half of 2025, primarily driven by a substantial settlement agreement with the State of New Jersey related to PFAS liabilities.

Chemours reports relatively flat net sales but a net loss for Q1 2025, impacted by restructuring charges and revisions to prior period financial statements.

Chemours' Q3 2024 results show a net loss, impacted by a goodwill impairment charge and restructuring costs, despite a slight increase in net sales.

Chemours' Q2 2024 results show a return to profitability, but are impacted by ongoing internal reviews and market challenges.

The Chemours Company reported a significant net loss in 2025, driven by substantial litigation charges and operational challenges in its Titanium Technologies and Advanced Performance Materials segments, despite growth in Thermal & Specialized Solutions.

Chemours' 10-K filing highlights its 'Pathway to Thrive' strategy, segment performance, and key risk factors for the fiscal year ended December 31, 2024.

Chemours has amended its agreement with David C. Shelton, extending his employment as Special Litigation Counsel by one year to December 31, 2024, and adjusting his compensation and benefits accordingly.

Calderon Gerardo Familiar, See Remarks of Chemours Co, reported a transaction in 943 shares of common stock on August 1, 2026.

Joseph T. Martinko, See Remarks of Chemours Co, reported a transaction in 663 shares of common stock on August 1, 2026.

Courtney Mather, a Director at The Chemours Company, reported transactions involving deferred stock units on June 30, 2026.

Director Mary Cranston acquired 7,182 shares of Chemours common stock, bringing her total beneficial ownership to 106,830.0129 shares.

Chemours Company Director Pamela Fletcher acquired 7,182 stock units as part of board compensation.

Chemours Company Director Alister Cowan acquired 7,182 stock units as part of board compensation.

Chemours is urging shareholders to vote in favor of Proposal 4, which requires an 80% approval, before the upcoming Annual Meeting on April 22nd to allow shareholders more influence over the company's future.

The Chemours Company is actively soliciting shareholders to vote on Proposal 4, an amendment to the Certificate of Incorporation, before the Annual Meeting of Shareholders on April 22, 2025.

The Chemours Company is urging shareholders to vote in favor of Proposal 4, which seeks to amend the company's Certificate of Incorporation to allow for amendments to be approved by a simple majority rather than a supermajority.

Chemours is urging shareholders to vote on several key proposals, including one to amend the Certificate of Incorporation to allow for majority voting on amendments to the Certificate and Bylaws.

The Chemours Company issued a supplement to its definitive proxy statement to correct an error in the reported beneficial ownership information of its directors, nominees, and executive officers.

Chemours outlines its refreshed 'Pathway to Thrive' strategy and welcomes new board members to drive long-term growth and shareholder value.

Vanguard Capital Management has reported beneficial ownership of 7,903,519 shares, representing 5.26% of the outstanding common stock of The Chemours Company.

Vanguard Portfolio Management reports beneficial ownership of 6.96% of Chemours Co. common stock as of March 31, 2026.

The Vanguard Group reported zero beneficial ownership in Chemours Co/The following an internal realignment that disaggregated its reporting.

Millennium Management and affiliates report reducing their beneficial ownership in The Chemours Company to 5.1%, falling below the 5% threshold as of July 1, 2025.

FMR LLC and Abigail P. Johnson reported a 3.4% beneficial ownership stake in Chemours Co common stock as of June 30, 2025, held for passive investment purposes.

The Vanguard Group has filed an amended Schedule 13G, revealing its beneficial ownership of 11.8% of Chemours Co/The's common stock as of June 30, 2025.